ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for vasculitis patients: avacopan safety trial underway
Disease control Recruiting nowThis study tests the long-term safety of avacopan in 300 adults with ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. Participants receive either avacopan or a placebo alongside standard treatments. The goal is to see if avacopan is saf…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 10:57 UTC
-
Immune cell therapy targets autoimmune diseases in early trial
Disease control Recruiting nowThis study tests a new treatment called NKX019, made from immune cells (natural killer cells) that are engineered to target and destroy certain immune cells causing disease. It is for people with autoimmune conditions like systemic sclerosis, inflammatory myopathies, or vasculiti…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 26, 2026 10:57 UTC
-
Engineered immune cells take aim at debilitating vasculitis
Disease control Recruiting nowThis early-stage trial tests a new treatment called CC-97540 for people with a severe form of ANCA-associated vasculitis, a disease where the immune system attacks blood vessels. The treatment uses a patient's own immune cells, modified to target and destroy harmful cells, aiming…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC